The company has failed to generate any commercial revenue over the last ten quarters while sustaining net losses of $9.4 million in 2024Q4.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 244K | 173K | -788K | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | -100% | 41.04% | 121.95% | - | - | - |
| Cost of Goods Sold | 161K | 212K | 405K | 205K | 148K | 115K | 148K | 157K | 130K | 92K | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | 53.28% | 53.18% | - | - | - |
| Gross Profit | -161K | -212K | -405K | -205K | -148K | -115K | -148K | -157K | 114K | 81K | -788K | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | 46.72% | 46.82% | 100% | - | - |
| Gross Profit Growth % | 24.06% | 47.65% | -97.56% | -38.51% | -28.7% | 22.3% | 5.73% | -237.72% | 40.74% | 110.28% | - | - | - |
| Operating Expenses | 25.95M | 17.65M | 20.03M | 17.32M | 13.93M | 14.07M | 11.06M | 10M | 9.06M | 12.46M | 4.81M | 3.75M | 3.9M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | 3713.93% | 7204.05% | -610.41% | - | - |
| Selling, General & Admin | 9.46M | 9.55M | 5.76M | 4.97M | 3.92M | 3.6M | 3.44M | 3.16M | 3.57M | 6.63M | 1.7M | 1.08M | 1.2M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | 1463.52% | 3830.06% | -215.1% | - | - |
| Research & Development | 0 | 8.29M | 14.27M | 12.35M | 10.01M | 10.47M | 7.62M | 6.84M | 5.49M | 5.84M | 3.11M | 2.66M | 2.69M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | 2250.41% | 3373.99% | -394.42% | - | - |
| Other Operating Expenses | 16.49M | -195K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7K | 7K |
| Operating Income | -25.95M | -19.29M | -20.03M | -17.32M | -13.93M | -14.07M | -11.06M | -10M | -9.06M | -12.46M | -4.81M | -3.74M | -3.91M |
| Operating Margin % | - | - | - | - | - | - | - | - | -3713.93% | -7204.05% | 610.41% | - | - |
| Operating Income Growth % | -34.54% | 3.73% | -15.66% | -24.33% | 0.97% | -27.17% | -10.62% | -10.36% | 27.29% | -159.11% | -28.54% | 4.25% | - |
| EBITDA | -25.79M | -19.07M | -19.63M | -17.12M | -13.78M | -13.95M | -10.91M | -9.84M | -8.93M | -12.37M | -4.73M | -3.67M | -3.83M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | -3660.66% | -7150.87% | 600.51% | - | - |
| EBITDA Growth % | -35.19% | 2.82% | -14.68% | -24.17% | 1.22% | -27.84% | -10.88% | -10.21% | 27.8% | -161.43% | -29.11% | 4.43% | - |
| D&A (Non-Cash Add-back) | 161K | 212K | 405K | 205K | 148K | 115K | 148K | 157K | 130K | 92K | 78K | 77K | 73K |
| EBIT | -9.46M | -17.86M | -19.1M | -17.19M | -13.83M | -14.07M | -10.58M | -10M | -9.06M | -12.32M | -4.54M | -3.97M | -3.92M |
| Net Interest Income | 800K | 1.76M | 914K | 106K | 57K | 237K | 236K | 59K | 132K | 14K | 5K | 0 | 177K |
| Interest Income | 809K | 1.77M | 926K | 119K | 69K | 245K | 243K | 66K | 139K | 61K | 10K | 59K | 183K |
| Interest Expense | 9K | 13K | 12K | 13K | 12K | 8K | 7K | 7K | 7K | 47K | 5K | 0 | 6K |
| Other Income/Expense | 800K | 293K | 926K | 119K | 86K | 233K | 473K | 236K | 244K | 173K | 3.92M | 604K | 187K |
| Pretax Income | -25.15M | -17.57M | -19.11M | -17.2M | -13.85M | -13.84M | -10.59M | -9.77M | -8.82M | -12.29M | -4.08M | -4M | -3.72M |
| Pretax Margin % | - | - | - | - | - | - | - | - | -3613.93% | -7104.05% | 517.26% | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | -1K | 6K | 8K | 0 | 734K | 243K | 6K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0.01% | -0.06% | -0.09% | 0% | -18.01% | -6.08% | -0.16% |
| Net Income | -25.15M | -17.57M | -19.11M | -17.2M | -13.85M | -13.84M | -10.59M | -9.77M | -8.83M | -12.29M | -4.08M | -4M | -3.72M |
| Net Margin % | - | - | - | - | - | - | - | - | -3617.21% | -7104.05% | 517.26% | - | - |
| Net Income Growth % | -43.15% | 8.06% | -11.08% | -24.24% | -0.07% | -30.66% | -8.37% | -10.71% | 28.19% | -201.52% | -2.03% | -7.36% | - |
| Net Income (Continuing) | -25.15M | -17.57M | -19.11M | -17.2M | -13.85M | -13.84M | -10.59M | -9.77M | -8.83M | -12.29M | -610K | -3.37M | -3.72M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -4.30 | -3.00 | -3.37 | -4.13 | -9.12 | -34.05 | -52.19 | -134.31 | -146.10 | -247.49 | -82.10 | -160.71 | -149.69 |
| EPS Growth % | -43.33% | 10.98% | 18.4% | 54.71% | 73.22% | 34.76% | 61.14% | 8.07% | 40.97% | -201.45% | 48.91% | -7.36% | - |
| EPS (Basic) | -4.30 | -3.00 | -3.37 | -4.13 | -9.12 | -34.05 | -52.19 | -134.31 | -146.10 | -247.49 | -82.10 | -160.71 | -149.69 |
| Diluted Shares Outstanding | 5.85M | 5.85M | 5.67M | 4.14M | 1.52M | 399.3K | 202.9K | 72.75K | 60.41K | 49.66K | 49.64K | 24.86K | 24.86K |
| Basic Shares Outstanding | 5.85M | 5.85M | 5.67M | 4.14M | 1.52M | 399.3K | 202.9K | 72.75K | 60.41K | 49.66K | 49.64K | 24.86K | 24.86K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - |
Liquidity and Delisting Risk
As evidenced by the company's financial statements over the last ten quarters, Check-Cap remains a pre-revenue entity with zero commercial sales, highlighting the significant gap between its technological development phase and the realization of any meaningful market-driven growth or sustainable revenue generation for the diagnostic platform.
The lack of top-line growth suggests that the company has yet to transition from a research-oriented entity to a commercial enterprise. Investors should monitor whether the absence of revenue is a result of prolonged regulatory hurdles or a fundamental inability to bring the C-Scan system to market.
According to reported figures, the company's operating expenses have remained elevated, with SG&A costs reaching $1.5 million in 2024Q4, underscoring a heavy reliance on administrative and regulatory spending despite the lack of any corresponding commercial activity or revenue-generating operations to offset these ongoing cash outflows.
The cost structure appears heavily skewed toward administrative overhead rather than direct R&D investment in recent periods. This expense discipline warrants further investigation, as it may indicate that the company is prioritizing corporate maintenance over the clinical milestones necessary for long-term viability.
Based on the provided income statement data, the reported net losses, which reached $9.4 million in 2024Q4, are significantly impacted by non-operating fluctuations, suggesting that headline EPS figures may not accurately reflect the underlying cash burn or the true operational efficiency of the business model.
The volatility in net income appears to be driven by accounting adjustments rather than core operational performance. Analysts should focus on cash-based metrics to understand the true rate of capital consumption, as the reported net income figures may mask the severity of the company's financial position.
As reported in recent filings, the company's inability to generate revenue while facing Nasdaq delisting warnings and shareholder activism suggests a precarious financial state, where the primary risk is not just margin compression, but the potential for a complete cessation of operations due to liquidity constraints.
The failure to achieve commercialization after years of development raises questions about the scalability of the C-Scan technology. Investors should consider that the current valuation may be based on speculative option value rather than any tangible progress toward a sustainable, revenue-generating business model.
Quick answers to the most common questions about buying CHEK stock.
For fiscal year 2024, Check-Cap Ltd. (CHEK) reported total revenue of $0.0M.
Check-Cap Ltd. (CHEK) reported a net loss of $25.1M for the fiscal year ending 2024.